Jiangsu Recbio Technology Announces Completion of H Share Full Circulation
Jiangsu Recbio Technology Announces Completion of H Share Full Circulation
Key Milestone Achieved: Over 141 Million Shares Converted to H Shares
Jiangsu Recbio Technology Co., Ltd. (Stock Code: 2179) has officially announced the successful completion of its H Share Full Circulation plan. This significant development marks a major milestone for the company and has important implications for its shareholders and potential investors.
Summary of Key Developments
-
Completion Date: The conversion of 141,953,489 unlisted shares into H Shares was finalized on April 29, 2026.
-
Listing Details: The newly converted H Shares were officially listed and commenced trading on The Stock Exchange of Hong Kong Limited at 9:00 a.m. on April 30, 2026.
-
Regulatory Approvals: The company previously received a filing notice from the China Securities Regulatory Commission (CSRC) and listing approval from the Stock Exchange, culminating in this completion.
Impact on Shareholding Structure
The completion of the H Share Full Circulation has led to a significant change in the company’s shareholding structure:
| Class of Shares |
Before Conversion & Listing |
After Conversion & Listing |
| Domestic Shares |
297,937,013 (47.59%) |
167,983,524 (26.83%) |
| Unlisted Foreign Shares |
12,000,000 (1.92%) |
0 (0.00%) |
| H Shares |
316,138,689 (50.50%) |
458,092,178 (73.17%) |
| Total Issued Shares |
626,075,702 (100%) |
626,075,702 (100%) |
Note: Percentages are rounded to two decimal places and may not add up precisely due to rounding.
What Shareholders Need to Know
-
Significant Increase in H Share Liquidity: With the conversion, H Shares now represent over 73% of the company’s total issued shares, up from 50.5%. This enhances the liquidity of the company’s shares in the Hong Kong market, potentially making the stock more attractive to international investors.
-
Elimination of Unlisted Foreign Shares: All unlisted foreign shares have been converted, simplifying the share structure and potentially contributing to greater transparency.
-
Potential for Share Price Impact: The dramatic increase in freely tradable H Shares may influence the share price, either through increased trading volumes and visibility or, conversely, through potential short-term downward pressure from increased supply.
-
Investor Caution: The company reminds shareholders and potential investors to exercise caution when trading in the company’s securities, given the significant changes in share structure and possible market impacts.
Corporate Governance Update
As of April 30, 2026, the board of directors is chaired by Mr. Xu Haoyu, with a mix of executive, non-executive, and independent non-executive directors, ensuring diversified oversight and governance.
Conclusion
The successful completion of H Share Full Circulation is a transformative event for Jiangsu Recbio Technology. The company is now better positioned to attract global capital and enhance its profile in international markets. However, shareholders should closely monitor market movements in the near term, as the increased liquidity and changes in the share structure could lead to heightened share price volatility.
Disclaimer: This article is for information purposes only and does not constitute investment advice. Investors should make their own assessments and consult with professional advisers before making any investment decision.
View RECBIO-B Historical chart here
